Rosenberg Jonathan, Fisher Westby G, Guerrero Mayra, Smart Steve, Levisay Justin, Feldman Ted, Salinger Michael
Evanston Hospital, Cardiology Division, Walgreen Building 3rd Floor, 2650 Ridge Ave, Evanston, IL 60201 USA.
J Invasive Cardiol. 2016 May;28(5):E44-8.
Pulmonary vein stenosis (PVS) is an uncommon but serious complication following radiofrequency ablation for atrial fibrillation. Occurrence of this complication has risen with increased rates of ablation procedures, with >50,000 AF ablation procedures performed per year, and can occur within weeks to months post procedure. Currently, the main therapies for PVS include percutaneous interventions with balloon angioplasty and stenting, but these treatments are complicated by a high rate of restenosis. The optimal treatment for recurrent pulmonary vein in-stent restenosis has not been determined. We describe the novel use of a paclitaxel drug-coated balloon for the treatment of in-stent restenosis of the pulmonary veins.
肺静脉狭窄(PVS)是心房颤动射频消融术后一种罕见但严重的并发症。随着消融手术率的增加,这种并发症的发生率也有所上升,每年进行超过50000例房颤消融手术,且可在术后数周内至数月内发生。目前,PVS的主要治疗方法包括球囊血管成形术和支架置入的经皮干预,但这些治疗因再狭窄率高而变得复杂。复发性肺静脉支架内再狭窄的最佳治疗方法尚未确定。我们描述了紫杉醇药物涂层球囊在治疗肺静脉支架内再狭窄中的新用途。